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Effi   cient initiation of an immune response relies 
on the interaction of APCs that have acquired 
antigen (Ag) and rare Ag-specifi  c T cells. DCs are 
widely accepted as the most potent APC because 
of their optimal positioning as sentinels in the 
periphery, their rapid migration to the draining 
LNs, their ability to acquire and present Ag on 
MHC class II, and their expression of the costim-
ulatory molecules CD80 and CD86. Once in the 
draining LN, Ag-bearing DCs make intimate 
contacts with Ag-specifi  c CD4+ T cells, so that 
the TCR is triggered by MHC class II and pep-
tide (“signal 1”) and CD28 is engaged by CD80/
CD86 expressed on the APC (“signal 2”), result-
ing in clonal expansion of Ag-specifi  c T cells (1). 
In addition to signals 1 and 2 being delivered 
by APC to T cells, T cells also provide signals to 
“condition” cognate APC. This process is exem-
plifi  ed by engagement of DC-expressed CD40 
by the TNF family member CD40L, which is 
induced on activated T cells (2). Conditioning, in 
combination with TLR signaling, provokes an 
infl  ammatory response from the DCs, including 
the up-regulation of CD80/CD86 and the secre-
tion of IL-12p70 (3–5).
To achieve this mutually activating inter-
action between DCs and rare Ag-specifi  c T cells, 
the spatial and temporal coordination of these 
encounters is facilitated by the existence of 
chemokine gradients, which guide DCs into 
the appropriate “niches” of the draining LN 
and recruit naive T cells via the high endo-
thelial venules (HEVs) (6). In the spleen, the 
organization of lymphocytes and the expres-
sion of these chemokines are governed in part 
by the lymphotoxin (LT) pathway (7). The 
LT-β receptor (LTβR) is a TNF family recep-
tor expressed on a variety of cell types, in-
cluding follicular dendritic cells, HEVs, DCs, 
and macrophages. The expression of its ligand, 
LTαβ, is restricted to activated lymphocytes, 
NK cells, and a subset of follicular B cells. 
Complicating this picture, an additional LTβR 
ligand, LIGHT (which is homologous to LTs, 
exhibits inducible expression, and competes 
with herpes simplex virus glycoprotein D for 
herpes virus entry mediator (HVEM), a recep-
tor expressed by T lymphocytes), is expressed 
by activated T cells and binds to another TNF 
family receptor, HVEM (8). Studies examin-
ing mice treated with a soluble decoy recep-
tor (LTβR-Ig) to inhibit the LT pathway, as 
well as LTα, LTβ, or LTβR-defi  cient mice, have 
shown that LTβR signaling is required for 
DC homeostasis, the maintenance of a marginal 
zone, the appearance of follicular dendritic cells 
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in the primary and secondary follicles, and the formation of 
germinal centers within the spleen (9).
Many rodent models of autoimmunity that are initiated 
by LN-resident T cells are sensitive to LTβR-Ig treatment 
(9). In these cases, the draining LN has somehow lost its 
ability to support eff  ective T cell responses. This could be 
because LTβR-Ig treatment has been shown to modulate 
peripheral LN addressin (PNAd) expression on the HEV, 
thus, impairing naive lymphocyte traffi   cking to the LN (10). 
Another possibility is that Ag-presenting DCs fail to migrate 
to or persist within the draining LN (11). Signaling of LTβR 
on DCs was shown to be important for DC homeostasis in 
both the spleen and the LNs (12). In an infl  ammatory setting, 
however, it is not known whether signals delivered to LTβR 
on DCs are relevant for their ability to prime T cells.
In this study, we have used two methods for inhibiting 
LTβR signaling. In one set of experiments, we have examined 
the eff  ects of inhibiting the LT–LIGHT pathways by adminis-
tering LTβR-Ig to wild-type animals. In a second set of ex-
periments, we have made use of an adoptive transfer approach 
where LTβR ligands are absent only on Ag-specifi  c CD4+ T 
cells in the context of an animal with intact LTβR signaling 
and normal lymphoid architecture. Using this comparative ap-
proach, we show that global LTβR signaling is required for 
maximal expression of CD86 on Ag-bearing DCs and for effi   -
cient priming of CD4 and CD8 T cells. However, to our sur-
prise, we found that in the context of a wild-type mouse with 
normal LTαβ expression and intact lymphoid microarchitec-
ture, expression of LTαβ on Ag-specifi  c T cells is required to 
condition DCs for CD4 and CD8 T cell priming ex vivo. 
Moreover, LTβ-defi  cient Ag-specifi  c T cells exhibit delayed 
proliferation and reduced cytokine secretion in vivo. In the 
absence of LTβ on Ag-specifi  c T cells, DC function can be 
recovered by administration of anti-CD40 agonistic antibody; 
likewise, the DC defect in the absence of CD40L on Ag-
specifi  c T cells can be overcome by administration of anti-
LTβR agonistic antibody. Therefore, we propose that CD40 
and LTβR signals can cooperate to promote full conditioning 
of DCs during the immune response to protein Ag.
RESULTS
LT𝗃R signaling controls DC function ex vivo
Given that LTβR signaling is required to maintain the organi-
zation of immune cells in the spleen, we evaluated the eff  ects 
of global LTβR signaling inhibition on the stimulatory capac-
ity of LN DCs during an immune response. To do this, we 
designed a system to recapitulate T cell–DC interactions dur-
ing a brief 36-h time period in vivo. Specifi  cally, mice were 
fi  rst treated with LTβR-Ig or control huIgG, followed by an 
adoptive transfer of OVA-specifi  c Thy1.1+ OTII T cells and 
subsequent subcutaneous immunization with OVA protein 
and LPS. Draining LNs were isolated 36 h after immuniza-
tion, and from them DCs were purifi  ed. To read-out DC 
function, we cocultured equal numbers of DCs derived from 
the LNs that drain OVA-immunized sites from control versus 
LTβR-Ig–treated mice with naive OTII T cells in vitro in the 
absence of exogenous Ag. DCs derived from control-treated 
OVA+LPS-immunized mice stimulated robust T cell prolif-
eration in the absence of any exogenously added OVA. In 
contrast, however, DCs derived from LTβR-Ig–treated mice 
failed to stimulate naive T cell proliferation ex vivo, and these 
DCs were virtually inert (Fig. 1 A, i). To eliminate the possi-
bility that DCs derived from LTβR-Ig–treated mice were 
simply dead/dying, we fed exogenous OVA323-339 peptide into 
our DC-OTII cocultures so that Ag is directly loaded onto 
MHC class II on the surface of DCs in vitro to induce po-
tent OTII T cell proliferation (Fig. 1 A, ii). As expected, 
in vitro addition of OVA323-339 peptide to OTII T cells cocul-
tured with DCs from either control Ig– or LTβR-Ig–treated 
mice resulted in OTII proliferation, although there was a 
two- to fourfold reduction in OTII proliferation if DCs 
were derived from LTβR-Ig–treated mice, suggesting that 
DCs from LTβR-Ig–treated mice are intrinsically not as 
Figure 1.  Signals mediated by the LT𝗃R control DC function. 
(A) The stimulating capacity of DCs from OVA-immunized mice treated 
with either control Ig or LTβR-Ig was evaluated ex vivo. Draining LN DCs 
were harvested from each huIgG control-treated (fi  lled circles) and LTβR-
Ig–treated (empty circles) mice and plated with naive OTII responder T cells 
either without (i) or with (ii) exogenous OVA peptide. (B) The experiment 
was repeated as in A, but using naive OTI responder T cells. Black bars, 
wells with 5,000 DCs; gray bars, 20,000 DCs. IFNγ secretion by responder 
OTII cells (C) or OTI cells (D) in the absence of added OVA peptide was 
quantifi  ed by measuring IFNγ levels in cultured supernatants by ELISA 
(gray bars, 20,000 input DCs; black bars, 140 input DCs). These experiments 
were performed three times on fi  ve mice per group with similar results.JEM VOL. 204, May 14, 2007  1073
ARTICLE
potent as DCs from control-treated mice. These data dem-
onstrate that DCs that acquire OVA in vivo absolutely re-
quire LTβR signaling for their function ex vivo, although 
DC function can be partially restored with addition of a 
strong agonistic peptide in vitro.
DCs derived from LTβR-Ig–treated mice were also 
poorly stimulatory when cocultured with naive OVA-specifi  c 
CD8 OTI T cells ex vivo, with OTI responder T cells exhibit-
ing a signifi   cant reduction in proliferation (P < 0.005 at 
20,000 DCs; P < 0.02 at 5,000 DCs; Fig. 1 B). As a measure 
of eff  ector function, IFNγ secretion from both OTII (Fig. 
1 C) and OTI T cells (Fig. 1 D) was quantifi  ed by ELISA. As 
expected, in the case of DCs derived from control-treated 
animals, high levels of T cell proliferation correlated with pro-
duction of IFNγ from OTII (IFNγ = 0.88 ± 0.13 ng/ml) 
and OTI T cells (IFNγ = 1.933 ± 0.35 ng/ml), whereas DCs 
derived from LTβR-Ig–treated mice failed to induce secre-
tion of detectable IFNγ from either OTII or OTI responder 
Figure 2.  Expression of some DC maturation markers, but not 
antigen processing by DCs, is dependent on LT𝗃R signaling. (A) Control 
or LTβR-Ig–treated mice received OTII T cells, were immunized with DQ-
OVA+LPS, and DCs from draining (v and vi) and nondraining (ii and iii) 
LNs were gated as indicated (i) and analyzed for their processed DQ-OVA 
content by evaluating the fl  uorescence emitted at 515 nm. Gray-fi  lled 
histograms are DCs from unimmunized mice, and empty histograms are 
DCs from DQ-OVA–immunized mice. Results are summarized in iv as a 
frequency of DCs that have acquired DQ-OVA, with gray bars representing 
unimmunized mice and black bars representing DQ-OVA–immunized 
mice. (B) Cryosections of popliteal LNs from either control-treated 
un  immunized or control versus LTβR-Ig–treated immunized mice were 
visualized with a 20× objective (Leica) for localization of proteolytically 
digested DQ-OVA and colocalization with CD11c+ DCs. B-cell follicles and 
the subcapsular sinus (SCS) are identifi  ed. (C) DC subsets were analyzed 
for DQ-OVA content by fi  rst eliminating TCR+CD19+ lymphocytes from 
analysis and gating on CD11c+ cells, as in A (i). Note that the CD11c Ab 
used in analyzing the CD11b+ DC subset was conjugated to a different 
fl  uorochrome than for the other FACS cocktails. (D) CD11c+ DQ-OVA+ DC 
were analyzed for the expression of CD80 and CD86. Percentage of CD86-
high DC was tabulated, as well as the mean fl  uorescence intensity (MFI) 
(E). The fl  ow cytometry experiment was performed twice on a total of 
10 mice per group. The immunohistochemistry images are representative 
examples of six different mice per group. Bar, 100 μm.1074  LYMPHOTOXIN-αβ AND DENDRITIC CELLS FUNCTION | Summers-deLuca et al.
T cells (OD did not register in the linear portion of the stan-
dard curve), despite residual OTI proliferation in this assay 
(Fig. 1 B). Collectively, these data demonstrate that LTβR 
signaling is required for DCs to stimulate proliferation and 
IFNγ production by naive T cells ex vivo.
Antigen processing is independent of LT𝗃R signaling
In these experiments, the in vitro activation of naive T cells 
by DCs relies entirely on Ag acquired in vivo. One explana-
tion for the impaired function of DCs from LTβR-Ig–treated 
animals is that they have failed to acquire Ag, either because 
DCs at the site of immunization (skin) do not migrate to the 
draining LNs, or because Ag uptake and processing is im-
paired. To evaluate these possibilities, we immunized mice 
with DQ-OVA, which is a self-stimulating OVA conjugate 
that emits a fl  uorescent signal upon proteolytic processing, 
such as that which occurs during Ag processing (13). There-
fore, we immunized control- or LTβR-Ig–treated C57BL/6 
mice that had received adoptively transferred WT-OTII 
T cells with DQ-OVA+LPS s.c. Mice were killed 18 h after 
immunization, and draining and nondraining LN DCs were 
identifi  ed as CD11c+TCRβ-CD19- cells (Fig. 2 A, i). DCs in 
the nondraining inguinal LNs of both control (Fig. 2 A, ii) 
and LTβR-Ig–treated (Fig. 2 A, iii) mice had background 
fl  uorescence equivalent to DCs from unimmunized animals, 
suggesting that they had not taken up and processed DQ-
OVA Ag. As expected, draining popliteal LN DCs from 
  control-treated (Fig. 2 A, v) mice acquired and processed 
DQ-OVA; however, there was no defect in the capacity of 
DCs from LTβR-Ig–treated animals to acquire Ag (Fig. 2 A, 
iv and vi), suggesting that LTβR-Ig treatment does not im-
pact Ag acquisition by DCs. DQ-OVA–derived fl  uorescence 
was localized predominantly to the T–B interface, and the 
subcapsular sinus of the draining LNs in both control and 
LTβR-Ig–treated animals, and DQ-OVA staining colocal-
ized with CD11c staining (Fig. 2 B). In addition, the DC 
subset that acquired DQ-OVA was found to be a CD11c+
CD11b+CD8−CD4−B220− DC subset in both control and 
LTβR-Ig–treated mice (Fig. 2 C). Collectively, acquisition 
of OVA by CD11b+ DC is not impaired in LTβR-Ig–
treated mice.
Expression of surface markers on DCs from LT𝗃R-Ig–
treated mice
Using the DQ-OVA reagent, we sought to determine if Ag-
bearing DCs from LTβR-Ig–treated mice exhibited any dif-
ference in accessory molecules that could account for their 
defective function ex vivo. We found that the level of ex-
pression of LTβR itself on DCs is stable and unaltered during 
infl  ammation in either treatment group (unpublished data). 
In addition, expression of MHCII and OX40-ligand were 
unaltered on DQ-OVA+ DCs from either treatment group, 
and we could not detect expression of CD70 at this early 
time point on DQ-OVA+ DCs in the draining LN (unpub-
lished data). Ligation of CD40 has been shown to be a potent 
inducer of the expression of CD80/CD86, even more so than 
LPS (4). Therefore, we evaluated if LTβR signaling was like-
wise required for up-regulation of these costimulatory mole-
cules by measuring the expression of CD80/CD86 on 
DQ-OVA+ DC from control versus LTβR-Ig–treated mice. 
Although CD80 levels were found to be normal, CD86 levels 
were substantially decreased (Fig. 2, D and E; P < 0.02 for 
E, i; P < 0.0007 for E, ii). Therefore, signaling through LTβR 
is required for full induction of CD86 on Ag-bearing DCs.
OTII T cells up-regulate LT𝗃R ligands in response to Ag
We next evaluated whether the expression of LTβR ligands 
(LIGHT, LTαβ) on Ag-activated T cells may be required for 
eff  ective T cell–DC communication. The expression kinetics 
of CD40L on Ag-specifi  c T cells in vivo has been shown to 
be diff  erent compared with what has been measured after in 
vitro stimulation (14). Because the kinetics of expression of 
LTαβ and LIGHT on Ag-specifi  c T cells in vivo has not 
been previously evaluated, we assessed the expression of 
LTαβ and LIGHT during the time window relevant to 
our DC function experiments by evaluating the expression of 
LTαβ and LIGHT on adoptively transferred Thy1.1+ OTII-
CD4+ T cells in vivo. Expression of the early activation 
markers CD69 and CD25 (not depicted) was used to identify 
Ag-activated T cells and, as expected, they were not ex-
pressed on naive CD4+ OTII T cells, but they were up-
regulated by 12 h and continued to be expressed 24 h after 
immunization with OVA (Fig. 3 A). Elevated expression of 
Figure 3.  Expression of LT𝗃R ligands on OTII CD4+ T cells in 
response to OVA antigen. Purifi  ed OTII T cells were adoptively transferred 
into C57BL/6 mice, which were then immunized with OVA. Thy1.1+ OTII 
T cells in the draining LNs were analyzed for the expression of CD69, LTαβ, 
and LIGHT. The expression of LTαβ and LIGHT on WT OTII T cells is demon-
strated with representative histograms from fi  ve mice (A), and a kinetic 
analysis of expression of CD69, LTαβ, and LIGHT was generated (B). The 
experiment was performed twice with similar results. Expression on re-
spective knockout T cells was insignifi  cant over background (not depicted). JEM VOL. 204, May 14, 2007  1075
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LTαβ and LIGHT was observed by 12 h (Fig. 3 A) and sus-
tained to varying degrees during the 36-h time course (Fig. 3 B). 
LIGHT was found to be more modestly up-regulated on 
OTII T cells in vivo, and the relatively low expression of 
LIGHT may be accounted for by rapid cleavage by matrix 
metalloproteinases (15). Interestingly, the peak expression of 
LTαβ coincides with that of CD69 (12 h), which corresponds 
with a period of intense contact between DCs and Ag-
specifi  c T cells (16). Because CD40L has also been shown to be 
up-regulated on OVA-specifi  c CD4+ T cells during the same 
36-h period (14), we hypothesized that in addition to CD40L, 
LTβR ligands may also play a role in DC conditioning.
Adoptive transfers of T cells from LT𝗃−/−-, LIGHT−/−-, 
and WT-OTII mice
To identify a contribution of T cell–derived LTβR ligands to 
DC function, we generated LTβ−/−- and LIGHT−/−-OTII 
mice as a source of ligand-defi  cient, Ag-specifi  c T cells. These 
knockout OTII T cells were then used as “DC-conditioning” 
T cells in adoptive transfer experiments. This experimental 
approach was imperative to dissect the role of LT pathway in 
DC activation, independent of the eff  ects of LT pathway on 
the lymphoid microenvironment. Therefore, we fi  rst assessed 
whether LTβ−/−- or LIGHT−/−-OTII T cells could become 
activated in response to OVA Ag in vivo by using an adoptive 
transfer and immunization scheme whereby donor CFSE-
labeled WT, LTβ−/−-, and LIGHT−/−-OTII T cells were 
transferred into C57BL/6 recipient mice 24 h before immu-
nization. Mice were immunized subcutaneously with OVA 
protein and LPS, and 36 h after immunization, draining LNs 
were harvested for IHC or fl  ow-cytometric analysis. In response 
to OVA immunization, WT, LTβ−/−-, and LIGHT−/−-OTII 
T cells each up-regulated CD25 and CD69 (Fig. 4 A), con-
fi  rming normal early activation of LTβ−/−- and LIGHT−/−-
OTII T cells in vivo.
LT𝗂𝗃 expressed on Ag-specifi  c T cells is required for DC 
function ex vivo
To address the relative DC-conditioning potential of T cell–
expressed LTαβ and LIGHT, we compared DC functionality 
from the draining LN of OVA-immunized C57BL/6 mice 
that received WT, LTβ−/−-, or LIGHT−/−-OTII T cells. In 
contrast to the experiments in Fig. 1, in this case, recipient 
mice have normal lymphoid microarchitecture, equivalent 
DC accumulation in the draining LN, and normal expression 
of LTβR ligands on all hematopoietic cells with the excep-
tion of the small transferred population of OVA-specifi  c 
T cells. DCs from each group of mice were harvested, purifi  ed, 
serially diluted, and plated with naive OTII and OTI re-
sponder cells to measure DC stimulatory capacity as in Fig. 1 
(A and B, respectively). In agreement with our fi  ndings from 
Fig. 1 A, DCs that interacted with WT-OTII T cells in vivo 
stimulated robust CD4 T cell proliferation (Fig. 4 B), with 
a stimulation index (SI) over background fl   ow-through 
controls of 331.7 ± 10.9 in the wells containing the highest 
number of DCs (Fig. 4 C). DCs that interacted with 
Figure 4.  Function of DCs conditioned by adoptively transferred 
WT-, LT𝗃−/−-, or LIGHT−/−-OTII T cells. (A) C57BL/6 mice received 
WT-, LTβ−/−-, or LIGHT−/−-OTII T cells and were immunized, and LN cell 
suspensions were gated on CD4 and Thy1.1 and analyzed for CD69 and 
CD25 at 36 h after immunization, with fi  lled histograms representing 
Thy1.1 T cells transferred into WT-unimmunized mice. (B) C57BL/6 mice 
received OVA-specifi  c WT- (fi  lled squares, fi  lled circles), LTβ−/−- (empty 
circles), or LIGHT−/−-OTII T cells (empty triangles), or were immunized 
or left unimmunized (fi  lled circles). At 36 h after immunization, draining 
LN DCs were plated with OTII responder T cells and incubated at 37°C for 
72 h. (C) Proliferation results from B are represented as a SI. CPM derived 
from OTII T cells cocultured with DCs was divided by CPM derived from 
OTII T cells cocultured with the same number of DC-depleted cells at the 
same cell input number for each individual group (internally controlled). 
Groups are responder OTII T cells stimulated by DCs conditioned in vivo 
by WT- (black bars), LTβ−/−- (gray bars), or LIGHT−/−-OTII T cells (open 
bars) and compared with DCs from unimmunized mice that received 
WT-OTII T cells (speckled bars). (D) A similar experiment was performed 
using DCs conditioned by WT-OTII versus LTβ−/−-OTII to stimulate naive 
responder OTI T cells using 15,000 or 30,000 DCs per well (black and 
gray bars, respectively). (E) IFNγ secretion by OTI CD8+ T cells from was 
evaluated by ELISA using 15,000 or 30,000 DCs per well (black and gray 
bars, respectively). OTII responder experiments were performed four 
times using DCs pooled from seven individual animals. OTI responder 
experiments were performed two times using DCs pooled from seven 
individual animals.1076  LYMPHOTOXIN-αβ AND DENDRITIC CELLS FUNCTION | Summers-deLuca et al.
LIGHT−/−-OTII T cells in vivo stimulated robust CD4 T cell 
proliferation roughly equivalent to DCs conditioned by WT-
OTII T cells, with a SI of 201.1 ± 26.3; however, at lower 
numbers of DCs, there was a modest decrease in proliferation 
(Fig. 4 B; not statistically signifi  cant). Strikingly, DCs that in-
teracted with T cells lacking LTαβ completely failed to stim-
ulate naive CD4+ T cell proliferation (P < 0.03 for 3,200 
DCs; P < 0.008 for 6,400 DCs). Indeed, DCs derived from 
OVA-immunized C57BL/6 mice that received LTβ−/−-OTII 
T cells were no better at stimulating naive responder OTII 
T cells in vitro than DCs derived from unimmunized mice (SI 
of 1.7 ± 1.1 for DCs conditioned by LTβ−/−-OTII T cells 
versus 1.0 ± 0.2 for DCs from unimmunized mice; P = 0.54). 
Likewise, in agreement with the data from Fig. 1 B, DCs that 
interacted with LTβ−/−-OTII T cells stimulated OTI T cells 
poorly ex vivo (P < 0.008 for 15,000 DCs; P < 0.03 for 
30,000 DCs; Fig. 4 D). This poor proliferation correlated with 
undetectable levels of IFNγ in culture supernatants (OD did 
not register in the linear portion of the standard curve) com-
pared with robust levels of IFNγ in culture supernatants of 
OTI T cells cocultured with DCs from mice that received 
WT-OTII T cells (5.19 ± 1.97 ng/ml; Fig. 4 E). These results 
identify a requirement for LTαβ on activated T cells for proper 
DC function in the context of a mouse with normal lym-
phoid microarchitecture.
LT𝗃–LT𝗃R interactions are required for optimal priming 
of Ag-specifi  c CD4 T cells in vivo
Using naive OTI and OTII T cells as “responder cells” in vitro, 
we have shown that DCs conditioned by LTβ−/− Ag-
specifi  c T cells in vivo have impaired function at 36 h after 
immunization. We next sought to determine if the DC de-
fect observed in vitro could be manifested in vivo. We did 
not observe any diff  erences in CD69 or CD25 up-regulation 
on WT versus LTβ−/− OVA-specifi  c T cells at 36 h (Fig. 4 A), 
which is reminiscent of Ag-specifi  c T cells primed in the 
absence of CD40 signaling where there are no obvious de-
fects in delivery of signal 1 or 2 to OVA-specifi  c T cells (Fig. 
6 A and [reference 17]). However,  close examination of cell 
division, as measured by loss of CFSE labeling, revealed a sta-
tistically signifi  cant reduction in the proportion of LTβ−/−-
OTII T cells that divided compared with WT-OTII T cells 
in the draining LNs of OVA-immunized mice (Fig. 5 A; P < 
0.02). To examine if this lag in cell division translates into 
impaired development of eff  ector function, we evaluated the 
frequency of IFNγ+ OTII T cells at day 5 after immuniza-
tion. We found a signifi  cant reduction in IFNγ+ LTβ−/−-
OTII T cells compared with their WT counterparts at this 
time-point (Fig. 5 A; P < 0.008). In addition, the level of 
IFNγ secreted by LTβ−/−-OTII T cells was signifi  cantly 
  reduced (Fig. 5 A; P < 0.0003).
Although in the fi  rst 36 h after immunization, endogenous 
WT helper cells are present at very low frequencies, endogenous 
LTαβ+ OVA-specifi  c T cells will become primed and ex-
pand at later time points in the immune response, potentially 
rescuing DC function in vivo. Therefore, we reassessed if 
LTβR signaling was important for CD4 T cell eff  ector func-
tion using the LTβR-Ig inhibitor to block any LTβR signal-
ing triggered by LTαβ on endogenous OVA-specifi  c T cells. 
In the context of global LTβR signal inhibition, we found 
that WT OTII T cells also produced signifi  cantly less IFNγ 
(Fig. 5 B; P < 0.05), which is in agreement with the observed 
reduction in IFNγ production by LTβ−/−-OTII T cells 
shown in Fig. 5 A. Therefore, consistent with a DC defect 
Figure 5.  LT𝗂𝗃–LT𝗃R interactions are required for optimal CD4 
priming in vivo. (A) C57BL/6 mice received CFSE-labeled, OVA-specifi  c 
WT- or LTβ−/−-OTII T cells, were immunized with OVA+LPS, or were left 
unimmunized. At 36 h after immunization, OTII CFSE content was as-
sessed, comparing baseline CFSE content for each individual genotype. At 
day 5 after immunization, secretion of IFNγ from OTII T cells was assessed 
by intracellular FACS. (B) C57BL/6 mice received OVA-specifi  c WT-OTII 
T cells, were treated with huIgG or LTβR-Ig, and were immunized with 
OVA+LPS. At day 7, the frequency of IFNγ+ OTII T cells was assessed. The 
experiments were performed twice with three to fi  ve mice per group in 
each experiment.JEM VOL. 204, May 14, 2007  1077
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manifested in vitro, LTβ−/−-OTII T cells exhibit suboptimal 
proliferation and eff  ector function in vivo.
CD40 signals are also required for DC conditioning 
and can rescue poorly conditioned DCs
It is well accepted that CD40 signaling on DCs is required for 
full expression of costimulatory molecules and conditions 
DCs for optimal T cell priming (3–5). To confi  rm that this is 
the case in our system, we generated CD40L−/−-OTII mice 
and performed adoptive transfer experiments identical to 
those in Fig. 4. Similar to LTβ−/−-OTII T cells, we observed 
no defect in the up-regulation of early activation markers 
CD69 and CD25 on CD40L−/−-OTII T cells in response 
to OVA immunization, and there did not appear to be any 
  defect in CD40L−/−-OTII T cell division, as measured by 
CFSE dilution (Fig. 6 A). However, DCs that were condi-
tioned by CD40L−/−-OTII T cells in vivo were profoundly 
impaired in their ability to induce naive OTII T cell prolif-
eration ex vivo (Fig. 6 B; P < 0.008 at both 6.3 × 103 and 
24.4 × 103 input DCs). Therefore, in our system, expression 
of CD40L and LTαβ on Ag-specifi  c T cells are both re-
quired for optimal DC conditioning in vivo.
Because both LTβ−/−- and CD40L−/− -OTII T cells fail 
to adequately condition DCs in vivo, CD40L and LTαβ pre-
sumably exert nonredundant functions for DC conditioning. 
Nonetheless, it is possible that very strong signals delivered 
through CD40 may be able to rescue defective DC function 
in mice that received LTβ−/−-OTII T cells. To test this, we 
coinjected either control Ab or agonistic anti-CD40 Ab with 
adoptively transferred LTβ−/−-OTII T cells and compared 
DC function ex vivo. In contrast to DCs derived from con-
trol Ab-treated mice, DCs from mice that received LTβ−/−
-OTII T cells and were concomitantly treated with anti-CD40 
agonistic Ab in vivo could stimulate the proliferation of both 
OTI and OTII T cells ex vivo (Fig. 6 C, i and ii). Likewise, 
strong signals delivered through the LTβR by administration 
of agonistic anti-LTβR Ab were able to recover DC func-
tion from mice that received CD40L−/−-OTII T cells as 
measured by the ability to provoke OTI and OTII T cell 
proliferation ex vivo (Fig. 6 C, iii and iv). Therefore,   although 
both LTαβ and CD40L expression on Ag-specifi  c T cells are 
both required for optimal DC conditioning in vivo, DC 
function can be recovered by enforced and sustained signaling 
through either CD40 or LTβR in vivo, suggesting potential 
cooperation between both pathways.
D  I  S  C  U  S  S  I  O  N 
We have shown that global inhibition of LTβR signaling 
impairs DC function. Our initial hypothesis was that LT 
pathway controls DC function by virtue of its overarching 
organization of the DCs within the LN stroma. However, in 
an experimental system uncomplicated by the myriad eff  ects 
exerted by LTβR-Ig treatment, expression of LTαβ on Ag-
specifi  c T cells is required for DC function ex vivo.
Before this study, there were some hints in the literature 
of a role for LTβR signaling in DC function independent of 
Figure 6.  Expression of CD40L on OTII T cells is required for DC 
function, and agonistic anti-CD40 or -LT𝗃R treatment can rescue DCs 
conditioned by LT𝗃−/−-OTII or CD40L−/−-OTII T cells, respectively. 
(A) C57BL/6 mice received CFSE-labeled WT- or CD40L−/−-OTII T cells, 
were immunized with OVA-LPS s.c., or were left unimmunized. CFSE con-
tent and the expression of CD69 and CD25 were measured by FACS at 
36 h after immunization. (B) Draining LN DCs from mice immunized as in 
A were plated with OTII responder T cells and incubated at 37°C for 72 h. 
Filled circles, WT-OTII T cells; empty circles, CD40L−/−-OTII T cells. 
(C) C57BL/6 mice received LTβ−/−- (i and ii) or CD40L−/−-OTII T cells 
(iii and iv), were immunized with OVA-LPS s.c., and were treated with the 
indicated agonistic Ab or control Ab. Purifi  ed draining LN DCs (20,000 DCs 
for i and ii; 10,000 DCs for iii and iv) were plated with OTI and OTII responder 
T cells and incubated at 37°C for 72 h. The experiments were performed 
two times with seven mice per group, except the experiment in C (i–ii), 
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LIGHT. For example, DCs derived from LTβ−/− mice ex-
hibit reduced IL-12 secretion in response to LPS stimulation 
ex vivo (18), and DC numbers in the spleen are sustained by 
LTαβ expression (11, 19). Furthermore, ligation of LTβR 
with agonistic antibodies in combination with GM-CSF 
induces the maturation of bone marrow–derived DCs (12). 
In parallel with these collective hints, we have now shown 
for the fi  rst time that activated Ag-specifi  c T cell must express 
LTαβ to condition DCs in vivo using CD4 proliferation/
IFNγ secretion as readouts. Importantly, we have been able 
to distinguish the eff  ects of LTβR signaling during the 
immune response independent of how these signals control 
the organization of the lymphoid microenvironment. We 
also observed that OTI CD8+ T cell proliferation was im-
paired when cocultured with DCs from LTβR-Ig–treated 
mice or mice that received LTβ−/−-OTII T cells, and the 
capacity of OTI responder T cells to secrete IFNγ was ab-
lated. Finally, we have shown that signaling through LTβR 
is required for the maximal up-regulation of CD86 on Ag-
bearing DCs, demonstrating that signals mediated by LTβR 
are critical at the earliest stages of DC maturation.
Several groups have demonstrated a role for LIGHT in 
mediating CD8 T cell responses, particularly alloresponses 
(20, 21). These defects in alloresponses in the absence of 
LIGHT-mediated signaling have prompted examinations 
into the role of LIGHT in DC-driven function. In agree-
ment, Morel et al. found that LIGHT could enhance CD40L-
delivered signals to induce a mature DC phenotype, although 
they did not confi  rm whether the LIGHT- mediated signals 
were through HVEM or LTβR on the DCs (22). We found 
that although expression of LIGHT on OTII T cells is not 
absolutely required for DC function, there was a modest, 
nonsignifi  cant reduction in DC function when DCs were 
plated at lower numbers. Therefore, we hypothesize that, in 
the context of protein Ag, LIGHT may play a secondary role 
in DC function, and can perhaps be compensated for by 
other stimulatory signals in vivo, such as CD40L.
We have found that DQ-OVA–bearing DCs from con-
trol versus LTβR-Ig–treated mice express equivalent levels 
of MHC class II, CD80, and OX40-ligand. This could ex-
plain why we found that LTβ−/−-OTII T cells exhibit rela-
tively normal early T cell activation. This is similar to what 
has been observed in CD40−/− mice (17), and in agreement, 
we fi  nd that CD40L−/−-OTII T cells also exhibit normal 
early T cell activation (Fig. 6). As opposed to an in vitro sys-
tem consisting of only DCs and Ag-specifi  c T cells, the con-
text of a highly infl   amed LN is presumably adequate for 
inducing initial T cell activation in vivo in cases where CD40 
or LTβR signals on DCs are absent. However, this in vivo 
context may not necessarily promote competent T cell im-
munity. Indeed, when we carefully examined CFSE dilution 
of LTβ−/−-OTII T cells we observed a lag in cell division. 
Moreover, a signifi  cantly lower frequency of LTβ−/−-OTII 
T cells develop the capacity to secrete IFNγ in vivo, which is 
consistent with previously reported global reductions in se-
rum IFNγ levels in LTβR-Ig–treated, collagen-immunized 
mice (23). Curiously, the CD4 response in LCMV-infected 
CD40L−/− mice was found to be relatively intact early on, 
but activated CD4 T cells were found to decrease in fre-
quency 5 d after immunization (24). Therefore, subtle prob-
lems in T cell–DC interactions caused by the absence of 
LTβR and/or CD40 signaling on DCs may result in more 
compounded defects in CD4 T cell function later in the im-
mune response.
There are several putative mechanisms that could explain 
the DC defect resulting from impaired LTβR signaling. Our 
experiments with DQ-OVA rule out a role for LTβR sig-
naling in mediating Ag uptake and processing, although we 
cannot eliminate Ag-presentation as a possible defect. 
Interestingly, Ag-bearing DCs from LTβR-Ig–treated mice 
exhibited a signifi  cant decrease in the expression of CD86 
that could lead to selective engagement of CTLA-4, rather 
than CD28, at the immunological synapse (25). In addition, 
we found that enforced signaling through CD40 with an 
agonistic Ab could restore DC function in mice that had 
received LTβ−/−-OTII T cells, suggesting that the two 
pathways may be complimentary. It should be noted that 
anti-CD40 treatment can induce LTαβ on resting B cells in 
vitro (26, 27) and in vivo (unpublished data). Thus, the eff  ects 
of anti-CD40 Ab may have been to provoke LTβR signal-
ing on DCs by provision of LTαβ in trans. This, combined 
with our observation that anti-LTβR agonistic Ab can rescue 
DC function in mice that had received CD40L−/−-OTII 
T cells suggests that LTβR signaling in DCs may provide 
  important DC maturation signals downstream of CD40 acti-
vation. However, it should be noted that treatment with 
  agonistic Abs over the entire 36-h time course of our experi-
ment will result in signaling of other receptor-positive cells, 
including stromal cells, which could induce the secretion of 
unidentifi  ed factors that enhance DC function. Nonetheless, 
under circumstances where agonistic Abs are not administered, 
our data show that CD40L expression on Ag-activated T cells 
cannot compensate for the absence of LTαβ expression and 
vice versa.
This nonredundant role for CD40 versus LTβR signaling 
in DC function is curious, and whether this is caused by an 
altered “signalsome” assembled by CD40 versus LTβR war-
rants examination. Signals delivered by CD40 have been 
shown to use TNF receptor–associated factor 6 (TRAF6) for 
their exerted eff  ects in DCs (28). However, a TRAF6 consensus-
binding site (PXEXX) is lacking in LTβR, and LTβR does 
not coimmunoprecipitate with TRAF6 (28), thus, revealing a 
potential diff  erence between these two TNF family receptors. 
In addition, although both CD40 and LTβR activate the al-
ternative and canonical NFκB pathways, one could imagine a 
scenario where CD40 and LTβR exert qualitatively and tem-
porally distinct signaling cascades in maturing DCs, resulting 
in the expression of diff  erent sets of genes that shape the in-
fl  ammatory response. It is also possible that LTβR signaling 
has a particular propensity to activate the alternative NFκB 
pathway in DCs (29), and this may be highly relevant to DC 
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Our data provide a potential explanation for the effi   cacy 
of LTβR-Ig treatment in many autoimmune disease models 
and suggest that this effi   cacy may be caused by poor DC 
function. This could, in turn, result in the generation of 
“tolerogenic” DCs. For example, although LTβR-Ig treat-
ment has no eff  ect on the initiation of relapsing-remitting 
EAE (R-EAE), this treatment prevents subsequent relapses, 
suggesting that encephalogenic T cells have acquired a toler-
ized phenotype in this setting (30). Collectively, we hypoth-
esize that T cells primed by DCs that do not receive signals 
through the LTβR ultimately fail to acquire eff  ector func-
tion; thus, LTβR may be providing unique signals to DCs 
that ultimately shape infl  ammatory T cell responses.
MATERIALS AND METHODS
Mice. WT C57BL/6 mice were either bred in-house or obtained from The 
Jackson Laboratory. C57BL/6 OTII Thy1.1+ transgenic mice (31) were ob-
tained from the Jackson Laboratory and were bred in-house. LTβ−/− mice 
were generated using C57BL/6 embryonic stem cells (32), and were purchased 
from B&K Universal. LIGHT−/− mice were generated by K. Pfeff  er (21) and 
were backcrossed to C57BL/6 for at least seven generations. The C57BL/6 
background for LIGHT−/− mice was confi  rmed by performing a tail skin 
graft experiment with LIGHT−/− tail tissue transplanted to C57BL/6 tails 
(unpublished data). No rejection was observed during a 6-wk period, indicat-
ing that for the LIGHT−/− mice, genes governing graft rejection were de-
rived from the C57BL/6 background. Each LTβ−/− and LIGHT−/− mouse 
was crossed with OTII Thy1.1 males. The LT pathway has been implicated in 
the maintenance of mature thymic medullary epithelial cells, as well as thymic 
expression of the autoimmune regulator gene (33). We evaluated thymic devel-
opment of T cells in the ligand knockout TCR transgenic mice and noted 
normal thymic cellularity and unaltered frequency of all thymic subsets in each 
genotype (Fig. S1, available at http://www.jem.org/cgi/content/full/jem
.20061968/DC1). All animals were housed in specifi  c pathogen-free condi-
tions. In all cases, 6–10-wk-old age-matched male mice were used for com-
parative studies. All experiments were performed according to the University 
of Toronto approved animal use protocols.
T cell purifi  cations and adoptive transfers. Single-cell suspensions of 
LN and spleen from WT and knockout OTII donor mice (spleen only from 
LTβ−/−-OTII mice), as well as OTI donor mice, were prepared. CD4+ 
and CD8+ T cells were enriched using CD4+ T-cell negative selection and 
CD8+ T-cell negative selection magnetic beads, respectively (Stem Cell 
Technologies). After purifi  cation, 5 × 107 OTII T cells/ml were stained 
in 2.5 nM CFSE (Invitrogen) in PBS for 10 min at 37°C. Enrichment for 
T cells was confi  rmed by fl  ow cytometry and was typically 85–95% pure. 
1–3 × 106 CD4+ T cells were injected i.v. in the tail vein of each mouse 1 d 
before immunization (day –1).
Immunizations and treatments. At the time of adoptive transfer, mice 
were treated with 100 μg of either LTβR-Ig fusion protein versus human Ig 
control protein (a gift from J. Browning, Biogen Idec, Inc., Cambridge, 
MA). 24 h later, mice were immunized s.c. in the back (day 0) with a total 
of 1 mg of OVA protein and 20 μg of LPS (Sigma-Aldrich) dissolved in a 
volume of 200 μl of PBS. Importantly, we have found in our system that 
ex vivo DC function was poor in the absence of LPS coadministration (Fig. S2, 
available at http://www.jem.org/cgi/content/full/jem.20061968/DC1). 
For i.p. immunizations, mice were immunized with a total of 1 mg of 
OVA protein and 20 μg of LPS. For in vivo experiments using agonistic 
anti-CD40 (a gift from R. Mittler, Emory University, Atlanta, GA) or 
anti-LTβR antibodies (a gift from J. Browning), mice were treated with 
100 μg of agonistic antibody or hamster Ab control at the time of immu-
nization, and received adoptive transfers and were immunized as for 
s.c. immunization.
Immunohistochemistry. Immunohistochemistry was performed as previ-
ously described (34). In brief, 36 h after immunization with OVA, mice 
were killed and immediately perfused with 30 ml of cold PBS. Draining 
popliteal LNs were collected and embedded in OCT compound (Tissue-
Tek) and fl  ash frozen in a bath of 2-methylbutane chilled on dry ice. 5-μm-
thick cryostat sections were stained with antibodies to CD11c.
Antibodies and staining. Antibodies to Vβ5.1, Thy1.1, CD11c, and 
CD40L (MR1) were obtained from BD Biosciences. Antibodies to CD4, 
TCRβ, CD25, and CD19, as well as all streptavidin fl  uorescent conjugates, 
were obtained from eBioscience. Anti-LTβ hamster monoclonal antibody 
BBF6 and hamster antibody control HA4/8 were gifts from J. Browning and 
have been previously described (30). Antibodies to CD69 and CD11c were 
both gifts from T. Watts (University of Toronto, Toronto, Canada). T cell 
purity after magnetic bead isolation was based on the percentage of 
CD4+Thy1.1+Vβ5.1+ cells, and DC purity was based on the percentage of 
CD11c+MHC II+TCRβ-CD19- cells. Ligand expression on OVA-specifi  c 
OTII cells was determined by staining with anti-Thy1.1, anti-CD4, anti-
CD69, anti-CD25, and the respective ligand-specifi  c antibody cocktails. For 
LIGHT staining we fi  rst blocked with anti-LTβ BBF6, followed by LTβR-
Ig and PE-conjugated anti–human Ig (Jackson ImmunoResearch Labora-
tories); for LTαβ staining we stained with anti-LTβ BBF6, followed by 
FITC-conjugated anti–hamster Ig (Jackson ImmunoResearch Laboratories); 
for anti-CD40L staining, we stained with biotinylated MR1, followed by 
fl  uorochrome-conjugated streptavidin.
For intracellular IFNγ staining, cells were incubated for 5 h with 
OVA323-339 ex vivo (Hospital for Sick Children Peptide Facility, Toronto, 
ON) and subsequently stained with Ab against CD4, CD8, and Thy1.1 on 
ice for 30 min. Cells were washed three times and incubated in 100 μl of 
Cytofi  x/Cytoperm (BD Biosciences) for 20 min on ice. Cells were washed 
with Perm/Wash (BD Biosciences), and incubated with a PE- or APC-
  conjugated anti-IFNγ antibody (eBioscience) diluted in Perm/Wash for 
30 min on ice. Cells were washed twice and resuspended in Perm/Wash.
DC purifi  cations. LNs were suspended in Hank’s Buff  ered Salt Solution 
(Invitrogen), 10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 
and 1.8 mM CaCl2 supplemented with 1 mM collagenase D (Roche) and 
60 μg/ml DNase I. LNs were mashed with glass slides, and the suspensions 
were incubated at 37°C with 5% CO2 for 30 min. At this time, tissues were 
disrupted by pipetting up and down, and suspensions were further incubated 
at 37°C with 5% CO2 for 10 min. EDTA was added to a fi  nal concentration 
of 1 mM, and the cell suspension was incubated at room temperature for 
10 min. Cells were fi  ltered (70 μm), spun, and resuspended in PBS/1 mM 
EDTA/2% FBS. DCs were enriched using CD11c+ positive selection kit 
(Stem Cell Technologies). The LN-derived, DC-enriched suspension typi-
cally comprised 80% CD11c+MHCII+TCRβ−CD19− DC, whereas the 
DC-depleted “fl  ow-through” fraction did not contain detectable numbers 
of DCs (unpublished data).
DC stimulatory capacity assays. 36 h after s.c. immunization with OVA, 
mice were killed and DCs were purifi  ed from the draining LNs (axillary, in-
guinal, and brachial) by enriching DCs using CD11c+ positive selection kit. 
As a control, we plated the DC-depleted fraction with responder T cells and 
confi  rmed that DCs were the relevant, most potent APCs in our system 
(unpublished data). The DCs and fl  ow-through fractions were irradiated 
(2,000 rads) and plated in quadruplicate wells in serial dilutions in RPMI-
1640 medium (Sigma-Aldrich), 10% FBS/1% β-mercaptoethanol, 1% 
l-glutamine, 1% penicillin-streptavidin.
For responder cells, naive WT CD4+ OTII T cells and CD8+ OTI 
T cells were purifi  ed using negative selection beads (StemCell Technologies). 
They were plated with DCs or fl  ow-through cells at 3 × 104 cells/well. 
In some cases, exogenous OVA323-339 peptide was added to half of the wells 
at 2 μg/ml. DC–T-cell cocultures were incubated at 37°C with 5% CO2 for 
72 h. 100 μl of supernatant was removed for IFNγ quantifi  cation, and was 
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(GE Healthcare); cultures were incubated for an additional 18 h and [3H]Td 
incorporation was measured. To calculate the SI, counts derived from DC 
cocultures were compared internally with the stimulation potential of the 
fl  ow-through, DC-depleted fraction for each individual group.
ELISA. 96-well, round-bottom MaxiSorp immunoplates (Nunc) were 
coated overnight with anti–mouse IFNγ capture antibody (BD Biosciences). 
Nonspecifi  c binding was blocked using PBS/1% BSA before adding super-
natants. IFNγ was detected using biotinylated anti-IFNγ detection antibody 
(BD Biosciences), followed by HRP-conjugated SA (eBioscience), 2,2’-
Amino-bis-3-ethylbenzthiazoline-6-sulfonic acid substrate (Sigma-Aldrich) 
and H2O2. Optical density was read at 405 nm. The concentration of IFNγ 
was extrapolated from an IFNγ standard (BD Biosciences) using the linear 
portion of the titration curve.
Tracers. DQ-OVA was purchased from Invitrogen and diluted to 5 mg/ml in 
PBS (PBS). 100 μg of DQ-OVA was injected s.c. into the hind paw. 18 h 
later, draining popliteal LNs were harvested and DCs were analyzed for DQ-
OVA content by detecting emissions of 515 nm by fl  ow cytometry.
Online supplemental material. Fig. S1 shows the thymic profi  les of WT, 
LTβ−/−, LIGHT−/−, and CD40L−/− OTII mice. Fig. S2 shows that DCs 
require OVA+LPS in vivo to activate naive OTII T cells ex vivo.
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